세계의 항균제 내성 시장 : 약제 클래스별, 병원체별, 적응증별, 작용기서별 - 기회 분석 및 산업 예측(2023-2032년)

The antimicrobial resistance market is likely to experience a significant growth rate of 7.6% from 2023-2032 owing to increasing market demand from pharmaceutical sector - Allied Market Research

Resistance to antimicrobials often develops in microorganisms over time because of genetic changes that occur during their reproductive cycles. Changes in the DNA may result in barriers that prevent antimicrobials from reaching the cell of microbe or may develop the ability to create enzymes that are able to counteract effects of the antimicrobial.

Antimicrobial resistance is significantly influenced by the overuse of antibiotics. Resistance to antimicrobials is heavily influenced by the excessive use of antibiotics. There is a higher chance of leaving behind resilient microbes when antibiotic treatments are too short, weak, or inappropriate for the specific infection. Moreover, antibiotics are often prescribed unnecessarily for viral infections such as colds, flu, or mild illnesses, which do not respond to antibiotics. Overprescribing leads to the unnecessary exposure of bacteria to these drugs, increasing the risk of resistance.

In addition, repeated exposure of microbes to antimicrobials, as well as contact with other already resistant microbes, provides numerous opportunities for resistance to develop and spread. Therefore, it is crucial to use antimicrobials appropriately to minimize the risk of antimicrobial resistance.

Furthermore, the rise in government initiatives to combat this antimicrobial resistance is the key factor which boosts the growth of the antimicrobial resistance market. For instance, the Global Antimicrobial Resistance Research & Development (AMR R&D) Hub is a collaboration of governments, non-governmental donor organizations, and intergovernmental organizations that use a One Health strategy to solve difficulties and increase coordination and collaboration in global AMR R&D.

On the other hand, the high cost of these novel therapeutics is expected to act as a restraint to the market growth. R&D of these antimicrobial candidates is expensive leading to higher cost of the products. This becomes difficult for people in lower-income countries to afford high-cost advanced antimicrobials and avoid antimicrobial resistance which may hinder market growth to some extent.

However, robust pipeline of antibiotic treatments to combat antimicrobial resistance is expected to offer lucrative opportunities for the growth of the market during the forecast period. Researchers and pharmaceutical companies have developed innovative therapies and treatments to combat antimicrobial resistance, providing potential new treatment options. In addition, the development of innovative antibiotics offers healthcare providers a wider range of treatment options. Having multiple effective antibiotics with different mechanisms of action can improve the chances of successfully treating infections, even those caused by highly resistant bacteria. This is expected to effectively overcome the threat of antimicrobial resistance and thus contribute to market growth during the forecast period.

The antimicrobial resistance market is segmented on the basis of drug class, pathogen, indication, mechanism of action, and region. On the basis of drug class, the market is classified into combination therapies, tetracyclines, cephalosporins, glycopeptides and lipoglycopeptides, oxazolidinones and others. On the basis of pathogen, the market is segmented into E. coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Staphylococcus aureus, Enterococcus Spp and others.

On the basis of on disease type, the market is segmented into complicated urinary tract infections (cUTI), blood stream infections, acute bacterial skin and skin structure infections (ABSSSI), hospital acquired bacterial pneumonia and ventilator acquired bacterial pneumonia (HABP and VABP), community acquired pneumonia (CAP) and Others. On the basis of mechanism of action, the market is categorized into protein synthesis inhibitors, cell wall synthesis inhibitors, and others. On the basis of region, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major key players that operate in the global antimicrobial resistance market are Alkem Laboratories Ltd, Innoviva, Inc., Pfizer Inc., Merck & Co., Inc., Acurx Pharmaceuticals, Inc., Basilea Pharmaceutica Ltd, Cumberland Pharmaceuticals Inc., Wockhardt Limited, Paratek Pharmaceuticals, Inc., and Nabriva Therapeutics plc.

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the antimicrobial resistance market analysis from 2022 to 2032 to identify the prevailing antimicrobial resistance market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the antimicrobial resistance market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global antimicrobial resistance market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

• Quarterly Update and* (only available with a corporate license, on listed price)
• 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
• Free Upcoming Version on the Purchase of Five and Enterprise User License.
• 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
• 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 20% is equivalent to 3 working days of free work, applicable once)
• Free data Pack on the Five and Enterprise User License. (Excel version of the report)
• Free Updated report if the report is 6-12 months old or older.
• 24-hour priority response*
• Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline talk to the sales executive to know more)

• Regulatory Guidelines
• Additional company profiles with specific to client's interest
• Additional country or region analysis- market size and forecast
• Expanded list for Company Profiles
• Historic market data

Key Market Segments

By Indication

• Complicated Urinary Tract Infections (cUTI)
• Blood stream infections
• Acute bacterial skin and skin structure infections (ABSSSI)
• Hospital acquired bacterial pneumonia and ventilator acquired bacterial pneumonia (HABP and VABP)
• Community acquired pneumonia (CAP)
• Others

By Drug Class

• Combination therapies
• Tetracyclines
• Cephalosporins
• Glycopeptides and Lipoglycopeptides
• Oxazolidinones
• Others

By Mechanism of Action

• Protein Synthesis Inhibitors
• Cell Wall Synthesis Inhibitors
• Others

By Pathogen

• Klebsiella pneumoniae
• Pseudomonas aeruginosa
• Staphylococcus aureus
• Enterococcus Spp
• Others
• Escherichia coli

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
• LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

Key Market Players:

• Pfizer Inc.
• Cumberland Pharmaceuticals
• Acurx Pharmaceuticals, Inc.
• Paratek Pharmaceuticals Inc
• Alkem Laboratories Ltd.
• Nabriva Therapeutics plc
• Innoviva, Inc
• Basilea Pharmaceutica Ltd
• Wockhardt Limited.
• Merck & Co., Inc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

• 1.1. Report description
• 1.2. Key market segments
• 1.3. Key benefits to the stakeholders
• 1.4. Research Methodology
  • 1.4.1. Primary research
  • 1.4.2. Secondary research
  • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

• 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

• 3.1. Market definition and scope
• 3.2. Key findings
  • 3.2.1. Top impacting factors
  • 3.2.2. Top investment pockets
• 3.3. Porter's five forces analysis
  • 3.3.1. Low bargaining power of suppliers
  • 3.3.2. Low threat of new entrants
  • 3.3.3. Low threat of substitutes
  • 3.3.4. Low intensity of rivalry
  • 3.3.5. Low bargaining power of buyers
• 3.4. Market dynamics
  • 3.4.1. Drivers
    • 3.4.1.1. Overuse and misuse of antibiotics
    • 3.4.1.2. Rise in prevalence of antimicrobial resistance bacterial infections
    • 3.4.1.3. Growth in burden of antimicrobial resistance

• 3.4.2. Restraints
  • 3.4.2.1. Global shortage of innovative antibiotics to combat antimicrobial resistance

• 3.4.3. Opportunities
  • 3.4.3.1. Surge in initiative to tackle antimicrobial resistance (AMR) globally

CHAPTER 4: ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS

• 4.1. Overview
  • 4.1.1. Market size and forecast
• 4.2. Combination therapies
  • 4.2.1. Key market trends, growth factors and opportunities
  • 4.2.2. Market size and forecast, by region
  • 4.2.3. Market share analysis by country
• 4.3. Tetracyclines
  • 4.3.1. Key market trends, growth factors and opportunities
  • 4.3.2. Market size and forecast, by region
  • 4.3.3. Market share analysis by country
• 4.4. Cephalosporins
  • 4.4.1. Key market trends, growth factors and opportunities
  • 4.4.2. Market size and forecast, by region
  • 4.4.3. Market share analysis by country
• 4.5. Glycopeptides and Lipoglycopeptides
  • 4.5.1. Key market trends, growth factors and opportunities
  • 4.5.2. Market size and forecast, by region
  • 4.5.3. Market share analysis by country
• 4.6. Oxazolidinones
  • 4.6.1. Key market trends, growth factors and opportunities
  • 4.6.2. Market size and forecast, by region
  • 4.6.3. Market share analysis by country
• 4.7. Others
  • 4.7.1. Key market trends, growth factors and opportunities
  • 4.7.2. Market size and forecast, by region
  • 4.7.3. Market share analysis by country

CHAPTER 5: ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN

• 5.1. Overview
  • 5.1.1. Market size and forecast
• 5.2. Escherichia coli
  • 5.2.1. Key market trends, growth factors and opportunities
  • 5.2.2. Market size and forecast, by region
  • 5.2.3. Market share analysis by country
• 5.3. Klebsiella pneumoniae
  • 5.3.1. Key market trends, growth factors and opportunities
  • 5.3.2. Market size and forecast, by region
  • 5.3.3. Market share analysis by country
• 5.4. Pseudomonas aeruginosa
  • 5.4.1. Key market trends, growth factors and opportunities
  • 5.4.2. Market size and forecast, by region
  • 5.4.3. Market share analysis by country
• 5.5. Staphylococcus aureus
  • 5.5.1. Key market trends, growth factors and opportunities
  • 5.5.2. Market size and forecast, by region
  • 5.5.3. Market share analysis by country
• 5.6. Enterococcus Spp
  • 5.6.1. Key market trends, growth factors and opportunities
  • 5.6.2. Market size and forecast, by region
  • 5.6.3. Market share analysis by country
• 5.7. Others
  • 5.7.1. Key market trends, growth factors and opportunities
  • 5.7.2. Market size and forecast, by region
  • 5.7.3. Market share analysis by country

CHAPTER 6: ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION

• 6.1. Overview
  • 6.1.1. Market size and forecast
• 6.2. Complicated Urinary Tract Infections (cUTI)
  • 6.2.1. Key market trends, growth factors and opportunities
  • 6.2.2. Market size and forecast, by region
  • 6.2.3. Market share analysis by country
• 6.3. Blood stream infections
  • 6.3.1. Key market trends, growth factors and opportunities
  • 6.3.2. Market size and forecast, by region
  • 6.3.3. Market share analysis by country
• 6.4. Acute bacterial skin and skin structure infections (ABSSSI)
  • 6.4.1. Key market trends, growth factors and opportunities
  • 6.4.2. Market size and forecast, by region
  • 6.4.3. Market share analysis by country
• 6.5. Hospital acquired bacterial pneumonia and ventilator acquired bacterial pneumonia (HABP and VABP)
  • 6.5.1. Key market trends, growth factors and opportunities
  • 6.5.2. Market size and forecast, by region
  • 6.5.3. Market share analysis by country
• 6.6. Community acquired pneumonia (CAP)
  • 6.6.1. Key market trends, growth factors and opportunities
  • 6.6.2. Market size and forecast, by region
  • 6.6.3. Market share analysis by country
• 6.7. Others
  • 6.7.1. Key market trends, growth factors and opportunities
  • 6.7.2. Market size and forecast, by region
  • 6.7.3. Market share analysis by country

CHAPTER 7: ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION

• 7.1. Overview
  • 7.1.1. Market size and forecast
• 7.2. Protein Synthesis Inhibitors
  • 7.2.1. Key market trends, growth factors and opportunities
  • 7.2.2. Market size and forecast, by region
  • 7.2.3. Market share analysis by country
• 7.3. Cell Wall Synthesis Inhibitors
  • 7.3.1. Key market trends, growth factors and opportunities
  • 7.3.2. Market size and forecast, by region
  • 7.3.3. Market share analysis by country
• 7.4. Others
  • 7.4.1. Key market trends, growth factors and opportunities
  • 7.4.2. Market size and forecast, by region
  • 7.4.3. Market share analysis by country

CHAPTER 8: ANTIMICROBIAL RESISTANCE MARKET, BY REGION

• 8.1. Overview
  • 8.1.1. Market size and forecast By Region
• 8.2. North America
  • 8.2.1. Key market trends, growth factors and opportunities
  • 8.2.2. Market size and forecast, by Drug Class
  • 8.2.3. Market size and forecast, by Pathogen
  • 8.2.4. Market size and forecast, by Indication
  • 8.2.5. Market size and forecast, by Mechanism of Action
  • 8.2.6. Market size and forecast, by country
    • 8.2.6.1. U.S.
    • 8.2.6.1.1. Market size and forecast, by Drug Class
    • 8.2.6.1.2. Market size and forecast, by Pathogen
    • 8.2.6.1.3. Market size and forecast, by Indication
    • 8.2.6.1.4. Market size and forecast, by Mechanism of Action
    • 8.2.6.2. Canada
    • 8.2.6.2.1. Market size and forecast, by Drug Class
    • 8.2.6.2.2. Market size and forecast, by Pathogen
    • 8.2.6.2.3. Market size and forecast, by Indication
    • 8.2.6.2.4. Market size and forecast, by Mechanism of Action
    • 8.2.6.3. Mexico
    • 8.2.6.3.1. Market size and forecast, by Drug Class
    • 8.2.6.3.2. Market size and forecast, by Pathogen
    • 8.2.6.3.3. Market size and forecast, by Indication
    • 8.2.6.3.4. Market size and forecast, by Mechanism of Action
• 8.3. Europe
  • 8.3.1. Key market trends, growth factors and opportunities
  • 8.3.2. Market size and forecast, by Drug Class
  • 8.3.3. Market size and forecast, by Pathogen
  • 8.3.4. Market size and forecast, by Indication
  • 8.3.5. Market size and forecast, by Mechanism of Action
  • 8.3.6. Market size and forecast, by country
    • 8.3.6.1. Germany
    • 8.3.6.1.1. Market size and forecast, by Drug Class
    • 8.3.6.1.2. Market size and forecast, by Pathogen
    • 8.3.6.1.3. Market size and forecast, by Indication
    • 8.3.6.1.4. Market size and forecast, by Mechanism of Action
    • 8.3.6.2. France
    • 8.3.6.2.1. Market size and forecast, by Drug Class
    • 8.3.6.2.2. Market size and forecast, by Pathogen
    • 8.3.6.2.3. Market size and forecast, by Indication
    • 8.3.6.2.4. Market size and forecast, by Mechanism of Action
    • 8.3.6.3. UK
    • 8.3.6.3.1. Market size and forecast, by Drug Class
    • 8.3.6.3.2. Market size and forecast, by Pathogen
    • 8.3.6.3.3. Market size and forecast, by Indication
    • 8.3.6.3.4. Market size and forecast, by Mechanism of Action
    • 8.3.6.4. Italy
    • 8.3.6.4.1. Market size and forecast, by Drug Class
    • 8.3.6.4.2. Market size and forecast, by Pathogen
    • 8.3.6.4.3. Market size and forecast, by Indication
    • 8.3.6.4.4. Market size and forecast, by Mechanism of Action
    • 8.3.6.5. Spain
    • 8.3.6.5.1. Market size and forecast, by Drug Class
    • 8.3.6.5.2. Market size and forecast, by Pathogen
    • 8.3.6.5.3. Market size and forecast, by Indication
    • 8.3.6.5.4. Market size and forecast, by Mechanism of Action
    • 8.3.6.6. Rest of Europe
    • 8.3.6.6.1. Market size and forecast, by Drug Class
    • 8.3.6.6.2. Market size and forecast, by Pathogen
    • 8.3.6.6.3. Market size and forecast, by Indication
    • 8.3.6.6.4. Market size and forecast, by Mechanism of Action
• 8.4. Asia-Pacific
  • 8.4.1. Key market trends, growth factors and opportunities
  • 8.4.2. Market size and forecast, by Drug Class
  • 8.4.3. Market size and forecast, by Pathogen
  • 8.4.4. Market size and forecast, by Indication
  • 8.4.5. Market size and forecast, by Mechanism of Action
  • 8.4.6. Market size and forecast, by country
    • 8.4.6.1. Japan
    • 8.4.6.1.1. Market size and forecast, by Drug Class
    • 8.4.6.1.2. Market size and forecast, by Pathogen
    • 8.4.6.1.3. Market size and forecast, by Indication
    • 8.4.6.1.4. Market size and forecast, by Mechanism of Action
    • 8.4.6.2. China
    • 8.4.6.2.1. Market size and forecast, by Drug Class
    • 8.4.6.2.2. Market size and forecast, by Pathogen
    • 8.4.6.2.3. Market size and forecast, by Indication
    • 8.4.6.2.4. Market size and forecast, by Mechanism of Action
    • 8.4.6.3. India
    • 8.4.6.3.1. Market size and forecast, by Drug Class
    • 8.4.6.3.2. Market size and forecast, by Pathogen
    • 8.4.6.3.3. Market size and forecast, by Indication
    • 8.4.6.3.4. Market size and forecast, by Mechanism of Action
    • 8.4.6.4. Australia
    • 8.4.6.4.1. Market size and forecast, by Drug Class
    • 8.4.6.4.2. Market size and forecast, by Pathogen
    • 8.4.6.4.3. Market size and forecast, by Indication
    • 8.4.6.4.4. Market size and forecast, by Mechanism of Action
    • 8.4.6.5. South Korea
    • 8.4.6.5.1. Market size and forecast, by Drug Class
    • 8.4.6.5.2. Market size and forecast, by Pathogen
    • 8.4.6.5.3. Market size and forecast, by Indication
    • 8.4.6.5.4. Market size and forecast, by Mechanism of Action
    • 8.4.6.6. Rest of Asia-Pacific
    • 8.4.6.6.1. Market size and forecast, by Drug Class
    • 8.4.6.6.2. Market size and forecast, by Pathogen
    • 8.4.6.6.3. Market size and forecast, by Indication
    • 8.4.6.6.4. Market size and forecast, by Mechanism of Action
• 8.5. LAMEA
  • 8.5.1. Key market trends, growth factors and opportunities
  • 8.5.2. Market size and forecast, by Drug Class
  • 8.5.3. Market size and forecast, by Pathogen
  • 8.5.4. Market size and forecast, by Indication
  • 8.5.5. Market size and forecast, by Mechanism of Action
  • 8.5.6. Market size and forecast, by country
    • 8.5.6.1. Brazil
    • 8.5.6.1.1. Market size and forecast, by Drug Class
    • 8.5.6.1.2. Market size and forecast, by Pathogen
    • 8.5.6.1.3. Market size and forecast, by Indication
    • 8.5.6.1.4. Market size and forecast, by Mechanism of Action
    • 8.5.6.2. Saudi Arabia
    • 8.5.6.2.1. Market size and forecast, by Drug Class
    • 8.5.6.2.2. Market size and forecast, by Pathogen
    • 8.5.6.2.3. Market size and forecast, by Indication
    • 8.5.6.2.4. Market size and forecast, by Mechanism of Action
    • 8.5.6.3. South Africa
    • 8.5.6.3.1. Market size and forecast, by Drug Class
    • 8.5.6.3.2. Market size and forecast, by Pathogen
    • 8.5.6.3.3. Market size and forecast, by Indication
    • 8.5.6.3.4. Market size and forecast, by Mechanism of Action
    • 8.5.6.4. Rest of LAMEA
    • 8.5.6.4.1. Market size and forecast, by Drug Class
    • 8.5.6.4.2. Market size and forecast, by Pathogen
    • 8.5.6.4.3. Market size and forecast, by Indication
    • 8.5.6.4.4. Market size and forecast, by Mechanism of Action

CHAPTER 9: COMPETITIVE LANDSCAPE

• 9.1. Introduction
• 9.2. Top winning strategies
• 9.3. Product Mapping of Top 10 Player
• 9.4. Competitive Dashboard
• 9.5. Competitive Heatmap
• 9.6. Top player positioning, 2022

CHAPTER 10: COMPANY PROFILES

• 10.1. Alkem Laboratories Ltd.
  • 10.1.1. Company overview
  • 10.1.2. Key Executives
  • 10.1.3. Company snapshot
  • 10.1.4. Operating business segments
  • 10.1.5. Product portfolio
  • 10.1.6. Business performance
  • 10.1.7. Key strategic moves and developments
• 10.2. Pfizer Inc.
  • 10.2.1. Company overview
  • 10.2.2. Key Executives
  • 10.2.3. Company snapshot
  • 10.2.4. Operating business segments
  • 10.2.5. Product portfolio
  • 10.2.6. Business performance
  • 10.2.7. Key strategic moves and developments
• 10.3. Acurx Pharmaceuticals, Inc.
  • 10.3.1. Company overview
  • 10.3.2. Key Executives
  • 10.3.3. Company snapshot
  • 10.3.4. Operating business segments
  • 10.3.5. Product portfolio
• 10.4. Basilea Pharmaceutica Ltd
  • 10.4.1. Company overview
  • 10.4.2. Key Executives
  • 10.4.3. Company snapshot
  • 10.4.4. Operating business segments
  • 10.4.5. Product portfolio
  • 10.4.6. Business performance
• 10.5. Cumberland Pharmaceuticals
  • 10.5.1. Company overview
  • 10.5.2. Key Executives
  • 10.5.3. Company snapshot
  • 10.5.4. Operating business segments
  • 10.5.5. Product portfolio
  • 10.5.6. Business performance
  • 10.5.7. Key strategic moves and developments
• 10.6. Wockhardt Limited.
  • 10.6.1. Company overview
  • 10.6.2. Key Executives
  • 10.6.3. Company snapshot
  • 10.6.4. Operating business segments
  • 10.6.5. Product portfolio
  • 10.6.6. Business performance
• 10.7. Paratek Pharmaceuticals Inc
  • 10.7.1. Company overview
  • 10.7.2. Key Executives
  • 10.7.3. Company snapshot
  • 10.7.4. Operating business segments
  • 10.7.5. Product portfolio
  • 10.7.6. Business performance
• 10.8. Nabriva Therapeutics plc
  • 10.8.1. Company overview
  • 10.8.2. Key Executives
  • 10.8.3. Company snapshot
  • 10.8.4. Operating business segments
  • 10.8.5. Product portfolio
  • 10.8.6. Business performance
  • 10.8.7. Key strategic moves and developments
• 10.9. Innoviva, Inc
  • 10.9.1. Company overview
  • 10.9.2. Key Executives
  • 10.9.3. Company snapshot
  • 10.9.4. Operating business segments
  • 10.9.5. Product portfolio
  • 10.9.6. Business performance
• 10.10. Merck & Co., Inc.
  • 10.10.1. Company overview
  • 10.10.2. Key Executives
  • 10.10.3. Company snapshot
  • 10.10.4. Operating business segments
  • 10.10.5. Product portfolio
  • 10.10.6. Business performance